ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

DeVita Era At NCI One Of New Programs, Remarkable Stability

August 19, 1988

Shorter, Simpler Consent Form Proposed For Phase I Trials

July 31, 2009

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

September 20, 1991

NCI Budget of $1.4 Billion Seems Assured, Barring GRH Cut, Veto; Organ Systems Renewal Confirmed

October 17, 1986

Nutrition Research Priority Areas Outlined By NCI

December 6, 1974

Arthur James, Ohio Founder Of Research Institute, Dead.

October 26, 2001